AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36796762 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of mutations at positions 212 and 366 of EBV latent membrane protein 1 (LMP1)
Number of subjects: 872
Study 36796762 — intervention group
Group type: COMPARATOR
Intervention: No mutations at positions 212 and 366 of EBV latent membrane protein 1 (LMP1)
Number of subjects: 872
Study 36796859 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and motor control exercises
Number of subjects: 123
Study 36796859 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and strengthening exercises
Number of subjects: 123
Study 36796859 — intervention group
Group type: COMPARATOR
Intervention: Education only
Number of subjects: 123
Study 36796986 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured semi-interactive stroke prevention package (SMS messages, videos, educational workbook)
Number of subjects: 4298
Study 36796986 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 4298
Study 36796986 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured semi-interactive stroke prevention package
Number of subjects: 4298
Study 36797015 — intervention group
Group type: EXPERIMENTAL
Intervention: Active NMES group (group A)
Number of subjects: 100
Study 36797015 — intervention group
Group type: COMPARATOR
Intervention: Placebo NMES group (group B)
Number of subjects: 100
Study 36797021 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile antenatal care clinic implementation
Number of subjects: 330
Study 36797021 — intervention group
Group type: COMPARATOR
Intervention: Open-label control group
Number of subjects: 330
Study 36797022 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoints stimulation (TEAS)
Number of subjects: 92
Study 36797022 — intervention group
Group type: COMPARATOR
Intervention: Sham TEAS (STEAS)
Number of subjects: 92
Study 36797025 — intervention group
Group type: EXPERIMENTAL
Intervention: PreventT2 Together, the adapted couple-based curriculum
Number of subjects: 12
Study 36797025 — intervention group
Group type: COMPARATOR
Intervention: CDC's PreventT2 curriculum designed for delivery to individuals
Number of subjects: 12
Study 36797036 — intervention group
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group block (n=30) using 20 mL of adrenalized bupivacaine 0.50%
Number of subjects: 60
Study 36797036 — intervention group
Group type: COMPARATOR
Intervention: Periarticular local anesthetic infiltration (n=30) using 60 mL of adrenalized bupivacaine 0.25%
Number of subjects: 60
Study 36797067 — intervention group
Group type: EXPERIMENTAL
Intervention: Preataxic participants
Number of subjects: 200
Study 36797067 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataxic patients
Number of subjects: 200
Study 36797067 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 200
Study 36797136 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Carbohydrate (LC) diet
Number of subjects: 20
Study 36797136 — intervention group
Group type: EXPERIMENTAL
Intervention: High Carbohydrate/High Sugar (HCS) diet
Number of subjects: 20
Study 36797136 — intervention group
Group type: EXPERIMENTAL
Intervention: High Carbohydrate/Fiber (HCF) diet
Number of subjects: 20
Study 36797201 — intervention group
Group type: EXPERIMENTAL
Intervention: 15.5 g carbohydrates
Number of subjects: 24
Study 36797201 — intervention group
Group type: EXPERIMENTAL
Intervention: 31 g carbohydrates
Number of subjects: 24
Study 36797201 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 24
Study 36797263 — intervention group
Group type: EXPERIMENTAL
Intervention: Governmental responses measured by the Containment and Health Index (CHI)
Number of subjects: 7645
Study 36797263 — intervention group
Group type: EXPERIMENTAL
Intervention: Multigravida exposed to COVID-19 or living in countries with a higher number of deaths due to COVID-19
Number of subjects: 7645
Study 36797263 — intervention group
Group type: EXPERIMENTAL
Intervention: Multigravida from countries with lower IHDI or CHI
Number of subjects: 7645
Study 36797263 — intervention group
Group type: EXPERIMENTAL
Intervention: More restrictive measures
Number of subjects: 7645
Study 36797356 — intervention group
Group type: EXPERIMENTAL
Intervention: BGB-A333 alone
Number of subjects: 39
Study 36797356 — intervention group
Group type: EXPERIMENTAL
Intervention: BGB-A333 plus tislelizumab
Number of subjects: 39
Study 36797356 — intervention group
Group type: EXPERIMENTAL
Intervention: BGB-A333 alone and in combination with tislelizumab
Number of subjects: 39
Study 36797394 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective lung ventilation (tidal volume set at 6 ml/Kg predicted body weight, PEEP 6 cmH2O)
Number of subjects: 0
Study 36797394 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 0
Study 36797461 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific mindfulness- and acceptance-based psychological intervention (MY-ENDO)
Number of subjects: 58
Study 36797461 — intervention group
Group type: EXPERIMENTAL
Intervention: Carefully matched non-specific psychological intervention (Non-specific)
Number of subjects: 58
Study 36797461 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (WL)
Number of subjects: 58
Study 36797461 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological interventions (MY-ENDO + Non-specific)
Number of subjects: 58
Study 36797481 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropifexor 10-90 μg
Number of subjects: 350
Study 36797481 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropifexor 140 μg
Number of subjects: 350
Study 36797481 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropifexor 200 μg
Number of subjects: 350
Study 36797481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 36797515 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation support programme including clinical training, supervision, appointing a family coordinator, toolkit, and fidelity measurements at baseline, 12, 18, and 24 months with on-site feedback and supervision.
Number of subjects: 14
Study 36797515 — intervention group
Group type: COMPARATOR
Intervention: No implementation support (control group) with fidelity measurements at baseline and 24 months without feedback.
Number of subjects: 14
Study 36797664 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib in combination with letrozole
Number of subjects: 2
Study 36797664 — intervention group
Group type: COMPARATOR
Intervention: Palbociclib in combination with letrozole
Number of subjects: 2
Study 36797680 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (ACT)
Number of subjects: 50
Study 36797744 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivoceranib (apatinib) 300 mg once daily in combination with pembrolizumab 200 mg every 3 weeks
Number of subjects: 5
Study 36797990 — intervention group
Group type: EXPERIMENTAL
Intervention: ETI therapy (elexacaftor/tezacaftor/ivacaftor)
Number of subjects: 20
Study 36798001 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment for transient congenital hypothyroidism (TCH)
Number of subjects: 111
Study 36798001 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment for permanent congenital hypothyroidism (PCH)
Number of subjects: 111
Study 36798001 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine dose of ≤3.95, ≤2.56, ≤2.19 and ≤2.12 μg/kg/day at 6 months, 1, 2 and 3 years of follow-up respectively
Number of subjects: 111
Study 36798001 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic factors for transient congenital hypothyroidism (TCH)
Number of subjects: 111
Study 36798001 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee epiphyses on X-ray at diagnosis
Number of subjects: 111
Study 36798044 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial factors associated with very infrequent HIV testing (VIT) among MSM
Number of subjects: 315
Study 36798078 — intervention group
Group type: EXPERIMENTAL
Intervention: SC methylnaltrexone (0.15 mg/kg for study 302; 8 mg or 12 mg based on body weight for study 4000)
Number of subjects: 364
Study 36798078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 364
Study 36798345 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Multisensory Rehabilitation (CMR), 3 times a week, 45 minutes per session for 6 weeks, followed by a 1-year follow-up.
Number of subjects: 26
Study 36798345 — intervention group
Group type: COMPARATOR
Intervention: Observation period (Control Group B) for 6 weeks followed by 6 weeks of CMR.
Number of subjects: 26
Study 36798353 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 blockade
Number of subjects: 0
Study 36798353 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined IL-6 and EGFR blockade
Number of subjects: 0
Study 36798485 — intervention group
Group type: EXPERIMENTAL
Intervention: Low oxytocin levels in AN/AtypAN-R
Number of subjects: 53
Study 36798485 — intervention group
Group type: EXPERIMENTAL
Intervention: Low oxytocin levels in AN/AtypAN-BP
Number of subjects: 53
Study 36798676 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-session tobacco cessation intervention with nicotine replacement therapy (NRT)
Number of subjects: 614
Study 36798676 — intervention group
Group type: COMPARATOR
Intervention: Re-engagement with Quitline treatment
Number of subjects: 614
Study 36798825 — intervention group
Group type: EXPERIMENTAL
Intervention: BD4QoL platform (intervention arm, n=280)
Number of subjects: 420
Study 36798825 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical practice (control arm, n=140)
Number of subjects: 420
Study 36798983 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I with < 5 hours of sleep
Number of subjects: 99
Study 36798983 — intervention group
Group type: COMPARATOR
Intervention: Sham-therapy with ≥ 5 hours of sleep
Number of subjects: 99
Study 36798983 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I with ≥ 5 hours of sleep
Number of subjects: 99
Study 36799346 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel preparation with mannitol
Number of subjects: 0
Study 36799346 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36799349 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program (DPP) intervention 1
Number of subjects: 0
Study 36799349 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program (DPP) intervention 2
Number of subjects: 0
Study 36799349 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36799536 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 0
Study 36799731 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-PASS
Number of subjects: 187
Study 36799731 — intervention group
Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 187
Study 36799736 — intervention group
Group type: EXPERIMENTAL
Intervention: ASTHMAXcel PRO mobile app usage
Number of subjects: 96
Study 36799736 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher eHealth literacy
Number of subjects: 96
Study 36799736 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 96
Study 36799736 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth literacy
Number of subjects: 96
Study 36799883 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-insulated needle RF device
Number of subjects: 24
Study 36799958 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline, dosage and duration not specified
Number of subjects: 0
Study 36799961 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine treatment, dosage and duration not specified
Number of subjects: 0
Study 36800111 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib (600 mg starting dose)
Number of subjects: 0
Study 36800111 — intervention group
Group type: COMPARATOR
Intervention: Ribociclib (400 mg single dose)
Number of subjects: 0
Study 36800111 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib
Number of subjects: 0
Study 36800158 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgical technique of gastric bypass with combined upper total and lower left partial fundoplication
Number of subjects: 1
Study 36800161 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 µg exenatide administered subcutaneously (s.c.) as a single dose
Number of subjects: 0
Study 36800161 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg liraglutide administered s.c. once daily for 21 days
Number of subjects: 0
Study 36800177 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study 36800177 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36800224 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-Body Intervention
Number of subjects: 0
Study 36800224 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36800246 — intervention group
Group type: EXPERIMENTAL
Intervention: 68 Ga-FAPI PET/CT
Number of subjects: 1
Study 36800246 — intervention group
Group type: COMPARATOR
Intervention: 18 F-FDG PET/CT
Number of subjects: 1
Study 36800262 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhynorm (generic propafenone)
Number of subjects: 76
Study 36800262 — intervention group
Group type: COMPARATOR
Intervention: Rytmonorm (brand name propafenone)
Number of subjects: 76
Study 36800262 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Rhynorm and Rytmonorm
Number of subjects: 76
Study 36800277 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfunctional adrenal adenomas (NFAA)
Number of subjects: 1154
Study 36800277 — intervention group
Group type: EXPERIMENTAL
Intervention: CortisolDST 83-137 nmol/L
Number of subjects: 1154
Study 36800277 — intervention group
Group type: EXPERIMENTAL
Intervention: CortisolDST ≥138 nmol/L
Number of subjects: 1154
Study 36800277 — intervention group
Group type: EXPERIMENTAL
Intervention: CortisolDST 50-82 nmol/L in patients younger than 65 years
Number of subjects: 1154
Study 36800433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0
Study 36800433 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study 36800443 — intervention group
Group type: EXPERIMENTAL
Intervention: SGN-CD228A (antibody-drug conjugate with MMAE)
Number of subjects: 0
Study 36800443 — intervention group
Group type: EXPERIMENTAL
Intervention: SGN-CD228A
Number of subjects: 0
Study 36800443 — intervention group
Group type: EXPERIMENTAL
Intervention: SGN-CD228A with glucuronide linker
Number of subjects: 0
Study 36800978 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised, distance-based exercise program (2 sessions of 60 minutes per week for 12 weeks)
Number of subjects: 200
Study 36800978 — intervention group
Group type: COMPARATOR
Intervention: Routine care control group
Number of subjects: 200
Study 36800978 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised, distance-based exercise program
Number of subjects: 200
Study 36800982 — intervention group
Group type: EXPERIMENTAL
Intervention: BEAM program (online group therapy and app-based mental health and parenting program)
Number of subjects: 46
Study 36801007 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact x-ray brachytherapy boost
Number of subjects: 141
Study 36801007 — intervention group
Group type: COMPARATOR
Intervention: External beam radiotherapy boost
Number of subjects: 141
Study 36801180 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS)
Number of subjects: 357
Study 36801197 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial Embolization (AE)
Number of subjects: 18
Study 36801197 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Ligation (LL)
Number of subjects: 18
Study 36801265 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral nudges delivered via electronic letters (9 different letters)
Number of subjects: 964870
Study 36801265 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no digitally delivered behavioral nudge)
Number of subjects: 964870
Study 36801265 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral nudges delivered via electronic letters
Number of subjects: 964870
Study 36801430 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable activity tracker plus structured feedback intervention
Number of subjects: 55
Study 36801430 — intervention group
Group type: COMPARATOR
Intervention: Wearable activity tracker alone
Number of subjects: 55
Study 36801448 — intervention group
Group type: EXPERIMENTAL
Intervention: MSDC-0602K (250 mg)
Number of subjects: 195
Study 36801448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 36801448 — intervention group
Group type: EXPERIMENTAL
Intervention: MSDC-0602K treatment in ZDF rats
Number of subjects: 195
Study 36801458 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided gastroenterostomy (EUS-GE)
Number of subjects: 64
Study 36801466 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus therapy
Number of subjects: 282
Study 36801466 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF-D levels
Number of subjects: 282
Study 36801605 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab, platinum, pemetrexed, and bevacizumab (PPAB cohort)
Number of subjects: 149
Study 36801605 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab, platinum, and pemetrexed (PPA cohort)
Number of subjects: 149
Study 36801605 — intervention group
Group type: EXPERIMENTAL
Intervention: PPAB cohort
Number of subjects: 149
Study 36801605 — intervention group
Group type: EXPERIMENTAL
Intervention: PPA cohort
Number of subjects: 149
Study 36801809 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton beam irradiation
Number of subjects: 14
Study 36801903 — intervention group
Group type: EXPERIMENTAL
Intervention: Active high-definition (HD) tDCS
Number of subjects: 59
Study 36801903 — intervention group
Group type: COMPARATOR
Intervention: Active conventional tDCS
Number of subjects: 59
Study 36801903 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 59
Study 36801916 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic fiber intervention for 10 days
Number of subjects: 20
Study 36801946 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated patients with breakthrough infections
Number of subjects: 118
Study 36801946 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated patients
Number of subjects: 118
Study 36801984 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 1.0 mg
Number of subjects: 1205
Study 36801984 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg
Number of subjects: 1205
Study 36801984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1205
Study 36802022 — intervention group
Group type: EXPERIMENTAL
Intervention: Palovarotene 5 mg
Number of subjects: 10
Study 36802022 — intervention group
Group type: EXPERIMENTAL
Intervention: Palovarotene 10 mg
Number of subjects: 10
Study 36802022 — intervention group
Group type: EXPERIMENTAL
Intervention: Palovarotene (both doses)
Number of subjects: 10
Study 36802031 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG)
Number of subjects: 387
Study 36802213 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36802320 — intervention group
Group type: EXPERIMENTAL
Intervention: QL1206
Number of subjects: 717
Study 36802320 — intervention group
Group type: COMPARATOR
Intervention: Denosumab
Number of subjects: 717
Study 36802321 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg every 2 weeks (Q2W)
Number of subjects: 241
Study 36802321 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg monthly (QM)
Number of subjects: 241
Study 36802321 — intervention group
Group type: COMPARATOR
Intervention: Placebo Q2W
Number of subjects: 241
Study 36802321 — intervention group
Group type: COMPARATOR
Intervention: Placebo QM
Number of subjects: 241
Study 36802388 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS coverage at 6, 12, and 24 months of ART
Number of subjects: 578
Study 36802388 — intervention group
Group type: EXPERIMENTAL
Intervention: Virological failure rate
Number of subjects: 578
Study 36802388 — intervention group
Group type: COMPARATOR
Intervention: Risk of virological failure
Number of subjects: 578
Study 36802389 — intervention group
Group type: EXPERIMENTAL
Intervention: Serrated lesions and polyps
Number of subjects: 231
Study 36802389 — intervention group
Group type: EXPERIMENTAL
Intervention: Males with proximal CRC
Number of subjects: 231
Study 36802389 — intervention group
Group type: EXPERIMENTAL
Intervention: Females with proximal CRC
Number of subjects: 231
Study 36802690 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-PLUS intervention (physiotherapy-led integrated care intervention)
Number of subjects: 29
Study 36802690 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 29
Study 36802690 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive Geriatric Assessment (CGA) in the ED
Number of subjects: 29
Study 36802715 — intervention group
Group type: COMPARATOR
Intervention: 6 mg efpeglenatide
Number of subjects: 1360
Study 36802715 — intervention group
Group type: COMPARATOR
Intervention: 4 mg efpeglenatide
Number of subjects: 1360
Study 36802715 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 1360
Study 36802753 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Snare Polypectomy (CSP)
Number of subjects: 4270
Study 36802753 — intervention group
Group type: COMPARATOR
Intervention: Hot Snare Polypectomy (HSP)
Number of subjects: 4270
Study 36802755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 563
Study 36802845 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (IPE)
Number of subjects: 0
Study 36802845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36802876 — intervention group
Group type: EXPERIMENTAL
Intervention: Andexanet alfa
Number of subjects: 479
Study 36802928 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience group sessions and 1:1 interviews
Number of subjects: 142
Study 36802983 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperspectral Imaging (HSI)
Number of subjects: 0
Study 36802983 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36803273 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (200,000 IU/1 ml of cholecalciferol)
Number of subjects: 117